Acesso livre
Acesso livre

Destaques

Efetividade da vacinação heteróloga com CoronaVac e Pfizer no Brasil.

10 Fev, 2022 | 13:51h

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil – Nature Medicine

 

Comentário no Twitter

 

Estudo randomizado | Tirzepatida subcutânea adicionada a insulina glargina titulada melhora o controle glicêmico de pacientes com diabetes tipo 2.

10 Fev, 2022 | 13:49h

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Tirzepatide for Patients With Type 2 Diabetes – JAMA

Comentário: SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D – AJMC

Conteúdos relacionados:

RCT: In patients with Type 2 Diabetes, Tirzepatide is associated with reduced weight, improved glycemic control, and lower risk of hypoglycemia compared to insulin glargine.

RCT: Once-weekly tirzepatide vs. once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes.

RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.

Diretrizes europeias para o tratamento de infecções causadas por bacilos Gram-negativos multirresistentes.

10 Fev, 2022 | 13:20h

European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM –European Society of intensive care Medicine) – Clinical Microbiology and Infection

Conteúdo relacionado: IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

Opinião | O desenvolvimento de diretrizes de práticas clínicas “é uma bagunça”.

10 Fev, 2022 | 13:19h

Development of clinical practice guidelines ‘is a mess’ – STAT

Diretriz atualizada da IDSA para Covid-19 agora apoia o uso de plasma convalescente em pacientes ambulatoriais com COVID-19 leve a moderada sob alto risco de progressão para doença grave.

10 Fev, 2022 | 13:18h

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 – Infectious Diseases Society of America

Conteúdo relacionado: [Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

 

Comentário no Twitter

 

OMS | Em 2 anos de pandemia de COVID, a maioria dos países ainda enfrenta importantes disrupções nos serviços de saúde.

10 Fev, 2022 | 13:16h

Two Years into COVID Pandemic, Most Countries Still Face Significant Health Service Disruptions – Health Policy Watch

Relatório original: Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic – World Health Organization

Estudo de coorte | Saúde mental e física 3 meses depois da infecção por SARS-CoV-2 (“long COVID”) entre adolescentes na Inglaterra.

10 Fev, 2022 | 13:15h

Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study – The Lancet Child & Adolescent Health

Ver também: Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study – The Lancet Child & Adolescent Health

Editorial: Assessing the impact of the pandemic in children and adolescents: SARS-CoV-2 infection and beyond – The Lancet Child & Adolescent Health

Comentário: Long COVID and kids: more research is urgently needed – Nature

Conteúdos relacionados:

A nationwide cohort study in Denmark showed Long Covid in children is rare and mainly of short duration.

Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

 

Comentário no Twitter (fio – clique para saber mais)

 

[Preprint] Vigilância ativa de miocardite e pericardite decorrentes da vacinação contra COVID-19 com vacinas do tipo mRNA em pessoas de 12-39 anos na Itália.

10 Fev, 2022 | 13:13h

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study -medRxiv

Conteúdos relacionados:

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Comentário no Twitter

 

Apesar de raro, o risco de inflamação cardíaca foi maior em quem recebeu vacina contra Covid da Moderna do que naqueles que receberam a dose da Pfizer.

10 Fev, 2022 | 13:11h

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer – CNBC

Conteúdos relacionados:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Perspectiva | Rastreamento de infecções por COVID-19: hora da mudança.

10 Fev, 2022 | 13:09h

Tracking COVID-19 infections: time for change – Nature

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.